论文部分内容阅读
目的观察使用心先安(环磷腺苷葡胺)联合卡托普利治疗顽固性心力衰竭的临床效果。方法 44例患者顽固性心力衰竭,随机分为两组,其中治疗组22例,对照组22例。治疗组在常规治疗的基础上组采用心先安联合卡托普利治疗4周,对照组采用常规治疗加强心利尿合剂治疗,观察患者治疗前后心脏功能变化,比较临床疗效。结果治疗组患者总有效率86.4%,除1例患者咳嗽厉害(但是没有退出治疗)外,均未出现明显不良反应。与对照组比较,差异有统计学意义(P<0.05)。结论心先安联合卡托普利治疗顽固性心力衰竭临床疗效肯定,安全系数较高,副作用较小,值得临床推广使用。
Objective To observe the clinical effect of the use of propranolol (cyclophosphamide) combined with captopril in the treatment of refractory heart failure. Methods Forty-four patients with refractory heart failure were randomly divided into two groups: 22 in the treatment group and 22 in the control group. On the basis of routine treatment, the treatment group was treated with xianxian combined with captopril for 4 weeks, and the control group was treated with xinliuji mixture by conventional treatment. The changes of cardiac function before and after treatment were observed, and the clinical curative effect was compared. Results The total effective rate of patients in treatment group was 86.4%. No obvious adverse reactions were found except for 1 patient who had cough (but did not quit treatment). Compared with the control group, the difference was statistically significant (P <0.05). Conclusions Xin Xiangan captopril in the treatment of refractory heart failure clinical efficacy of positive, higher safety factor, fewer side effects, it is worth to promote clinical use.